| 货号 | 4507/50 |
| 别名 | 3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3 |
| 供应商 | Tocris |
| 生物活性 | Selective inhibitor of T-type calcium channels (IC50 values are 270 and 310 nM for Cav3.3 and Cav3.2 respectively in a patch EP assay). Decreases burst activity in STN neurons; reduces cataleptic behaviour in an in vivo rat model of Parkinsons disease. Displays no significant inhibition of L- or N-type calcium channels, Kir6 (KATP) or KV11.1 (hERG) potassium channels. Orally active. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 纯度 | >99 % |
| 计算分子量 | 405.79 |
| 分子式 | C19H26Cl2N2< |
| 可溶性/溶解性 | Soluble to 100 mM in DMSO and to 100 mM in ethanol |
| 参考文献 | Galvanet al (2016) Lack of antiparkinsonian effects of systemic injections of the specific T-type calcium channel blocker ML218 in MPTP-treated monkeys. ACS Chem.Neurosci. PMID: 27596273. Xianget al (2011) The discovery and characterization of ML218: A novel, centrally active T-type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinsons disease. ACS Chem.Neurosci. 2 730. PMID: 22368764. |